Selling Your Company to an ESOP: The C Corp Rule in Section 1042.

A machine shop owner outside Ogden turns 63 this year with a private equity offer in hand and a second idea he likes better. Selling your company to an ESOP moves the business to the people who built it and, under IRC §1042, can defer every dollar of capital gains tax on the sale. He is going to get none of that deferral. His company is an S corporation, and §1042 reaches C corporation stock only.

Start with what counts as qualified securities. Section 1042(c)(1) wants employer securities as defined in §409(l), issued by a domestic C corporation with no stock outstanding that is readily tradable on an established securities market. It excludes anything the seller received in a distribution from a §401(a) plan or in a transfer under an option or purchase right governed by §83, §422, or §423. Founder stock is fine. Incentive stock option and employee stock purchase plan shares sit permanently outside the section.

The second gate is size. Under §1042(b)(2), immediately after the sale the plan has to own at least 30% of each class of outstanding stock, or 30% of the total value of all outstanding stock. A 10% toe-in-the-water sale earns no deferral. The third gate is time: §1042(b)(4) requires the seller to have held the stock for at least three years, so shares issued in a recapitalization to set up the deal wait another three years.

The fourth is the company's signature. Section 1042(b)(3) requires a verified written statement from the corporation consenting to the excise taxes in §4978 and §4979A. That consent puts the company on the hook if the plan resells the shares early or allocates them to the wrong people, and no election is valid without it.

He has two routes to the deferral and both cost something. He can revoke the S election and sell as a C corporation, which triggers §1362(g): the company cannot elect S status again for five taxable years without IRS consent. Or he can wait. Section 114 of the SECURE 2.0 Act extended §1042 to S corporation stock for sales after December 31, 2027, capped at 10% of the amount realized. On a $12,000,000 sale that is $1,200,000 of deferral, not $12,000,000.

Before he revokes anything, price what the S election is worth on the other side of the deal. An ESOP is a tax-exempt trust, and §512(e)(3) keeps its share of S corporation income out of unrelated business income tax, so a company owned 100% by an S corporation ESOP pays no federal income tax on operating profit at all. On $2,000,000 of annual profit that is roughly $420,000 a year against the 21% corporate rate, which outruns the federal tax on the sale below in about seven years. The catch is that the deferral belongs to the seller and the exemption belongs to the company. My default for a profitable S corporation is to leave the election alone, pay the capital gains tax, and keep the exemption for the company the employees now own. The C corporation route earns its keep when basis is near zero, margins are thin, and the seller intends to hold the replacement securities until death. If C corporation status is on the table anyway, price the QSBS exclusion at the same time.

The election does not forgive the gain, it parks it. Under §1042(d) the replacement securities take the old basis, $500,000 here, so the $11,500,000 reappears the day they are sold. Two things end the deferral: a sale, which recaptures the gain under §1042(e), or death, which steps the basis up under §1014 and erases it. That is the same buy, borrow, die arithmetic behind most concentrated-position planning, and it is why the election fits a 63-year-old better than a 45-year-old.

Section 1042(c)(4) defines qualified replacement property as securities issued by a domestic operating corporation, meaning one with more than 50% of its assets used in the active conduct of a trade or business, that did not have passive investment income above 25% of gross receipts in the taxable year before the purchase. Stocks and corporate bonds of ordinary US operating companies qualify. Mutual funds, ETFs, REITs, municipal bonds, and Treasury securities do not, and neither does stock of the issuing company or its controlled group. The replacement period in §1042(c)(3) runs from 3 months before the sale to 12 months after it, generous next to the 45 days a 1031 exchange allows.

The practical problem is a concentrated pile of individual securities the seller cannot sell. The standard answer is long-dated floating rate notes from large US issuers, pledged as collateral for a margin line, which leaves the notes in place while the cash gets used. It works and it is not free. The notes often run 40 years or longer, and a margin call in a credit selloff forces exactly the sale the structure exists to avoid.

The election goes on a statement attached to the return for the year of the sale, filed by the due date including extensions, under Treas. Reg. §1.1042-1T. The corporation's consent statement rides along with it. Separately, each purchase needs a statement of purchase describing the property, the date, and the cost, notarized within 30 days. Miss the notarization and the property is not qualified replacement property, which is a bad way to lose a seven-figure deferral.

Then live with §409(n). During the nonallocation period, which ends the later of 10 years after the sale or the allocation tied to the final payment on the acquisition loan, no shares from the sale can go to the seller, to relatives inside §267(c)(4), or to anyone owning more than 25% of any class of stock. Lineal descendants get a narrow carve-out capped at 5% of those shares. Violating it costs a 50% excise tax under §4979A. If the plan disposes of the shares inside three years, §4978 puts a 10% excise tax on the employer. The seller's own lost allocation is usually small. The one that stings is the child working in the business, held to a sliver of what every other employee receives.